| CTCF |
A549 (lung carcinoma) |
1 h with 100 nM Dexamethasone (Myers) |
Permissive
Robust
|
Homo sapiens |
ENCSR000AUE
|
MA0139.1
|
| CTCF |
A549 (lung carcinoma) |
1 h with 0.02% Ethanol (Myers) |
Permissive
Robust
|
Homo sapiens |
ENCSR000AUF
|
MA0139.1
|
| CTCF |
A549 (lung carcinoma) |
1 h with 100 nM Dexamethasone (Myers) |
Permissive
Robust
|
Homo sapiens |
ENCSR000BHV
|
MA0139.1
|
| CTCF |
A549 (lung carcinoma) |
1 h with 0.02% Ethanol (Myers) |
Permissive
Robust
|
Homo sapiens |
ENCSR000BHW
|
MA0139.1
|
| CTCF |
SK-N-SH (neuroblastoma) |
6 μM all-trans-retinoic acid (CHEBI:15367) for 48 hour |
Permissive
Robust
|
Homo sapiens |
ENCSR000BLX
|
MA0139.1
|
| CTCF |
T47D (invasive ductal carcinoma) |
1 h with 0.02% Dimethyl sufloxide (DMSO) (Myers) |
Permissive
Robust
|
Homo sapiens |
ENCSR000BNO
|
MA0139.1
|
| CTCF |
Ishikawa (endometrial adenocarcinoma) |
1 h with 0.02% Dimethyl sufloxide (DMSO) (Myers) |
Permissive
Robust
|
Homo sapiens |
ENCSR000BQE
|
MA0139.1
|
| CTCF |
LNCaP clone FGC |
12 hrs with 1 nM Methyltrienolone (R1881) (Crawford) |
Permissive
Robust
|
Homo sapiens |
ENCSR000DME
|
MA0139.1
|
| CTCF |
MCF7 (Invasive ductal breast carcinoma) |
45 min with 100 nM Estradiol (Crawford) |
Permissive
Robust
|
Homo sapiens |
ENCSR000DMS
|
MA0139.1
|
| CTCF |
SK-N-SH (neuroblastoma) |
6 μM all-trans-retinoic acid (CHEBI:15367) for 48 hour |
Permissive
Robust
|
Homo sapiens |
ENCSR000DXQ
|
MA0139.1
|
| CTCF |
LNCaP (prostate carcinoma) |
10 nM 17β-hydroxy-5α-androstan-3-one (CHEBI:16330) for 4 hour |
Permissive
Robust
|
Homo sapiens |
ENCSR673WZL
|
MA0139.1
|
| CTCF |
bipolar neuron |
0.5 μg/mL doxycycline hyclate (CHEBI:34730) for 4 day |
Permissive
Robust
|
Homo sapiens |
ENCSR066BZZ
|
MA0139.1
|
| CTCF |
22RV1 (prostate carcinoma) |
10 nM 17β-hydroxy-5α-androstan-3-one (CHEBI:16330) for 4 hour |
Permissive
Robust
|
Homo sapiens |
ENCSR847XGE
|
MA0139.1
|
| CTCF |
foreskin keratinocyte |
1mM calcium (CHEBI:86158) for 5 day |
Permissive
Robust
|
Homo sapiens |
ENCSR812FNU
|
MA0139.1
|
| CTCF |
foreskin keratinocyte |
1mM calcium (CHEBI:86158) for 2 day |
Permissive
Robust
|
Homo sapiens |
ENCSR036EGV
|
MA0139.1
|
| CTCF |
whole organism (development stage: embryonic) |
strain: CTCF-GFP, genotype: y[1] w[*]; P{y[+7.7] w[+mC]=CTCF-GFP.FPTB}attP40, sex:mixed |
Permissive
Robust
|
Drosophila melanogaster |
ENCSR661BEZ
|
MA0531.1
|
| CTCF |
embryonic stem cells |
Dnmt1/3a/3b KO |
Permissive
Robust
|
Mus musculus |
GSE30203
...
|
MA0139.1
|
| CTCF |
pro-B cells |
RAG1 KO |
Permissive
Robust
|
Mus musculus |
GSE21978
...
|
MA0139.1
|
| CTCF |
CD36+ erythroid cells |
BRG1 KD shLuc control |
Permissive
Robust
|
Homo sapiens |
GSE26501
...
|
MA0139.1
|
| CTCF |
CD36+ erythroid cells |
BRG1 RNAi KD |
Permissive
Robust
|
Homo sapiens |
GSE26501
...
|
MA0139.1
|
| CTCF |
G1E-ER4 (embryonic stem cells) |
24 hours differentiation of G1E-ER4 cells with 10 nM beta-estradiol (Hardison) |
Permissive
Robust
|
Mus musculus |
ENCSR000DIR
...
|
MA0139.1
|
| CTCF |
MEL cell line |
5 d with 2% Dimethyl sufloxide (DMSO) (Weissman) |
Permissive
Robust
|
Mus musculus |
ENCSR000ETE
...
|
MA0139.1
|
| CTCF |
B-cells |
stimulated |
Permissive
Robust
|
Mus musculus |
GSE43594
...
|
MA0139.1
|
| CTCF |
MCF7 (Invasive ductal breast carcinoma) |
oestrogen, CTCF siRNA |
Permissive
Robust
|
Homo sapiens |
GSE25021
...
|
MA0139.1
|
| CTCF |
MCF7 (Invasive ductal breast carcinoma) |
oestrogen |
Permissive
Robust
|
Homo sapiens |
GSE25021
...
|
MA0139.1
|
| CTCF |
MCF7 (Invasive ductal breast carcinoma) |
oestrogen |
Permissive
Robust
|
Homo sapiens |
GSE25021
...
|
MA0139.1
|
| CTCF |
HepG2 (hepatoblastoma) |
none |
Permissive
Robust
|
Homo sapiens |
GSE25021
...
|
MA0139.1
|
| CTCF |
dendritic cells |
LPS, 0 min |
Permissive
Robust
|
Mus musculus |
GSE36099
...
|
MA0139.1
|
| CTCF |
dendritic cells |
LPS, 120 min |
Permissive
Robust
|
Mus musculus |
GSE36099
...
|
MA0139.1
|
| CTCF |
dendritic cells |
LPS, 30 min |
Permissive
Robust
|
Mus musculus |
GSE36099
...
|
MA0139.1
|
| CTCF |
dendritic cells |
LPS, 60 min |
Permissive
Robust
|
Mus musculus |
GSE36099
...
|
MA0139.1
|
| CTCF |
CD34+ hematopoietic stem cells-derived proerythroblasts |
2-trimester fetal liver |
Permissive
Robust
|
Homo sapiens |
GSE36985
...
|
MA0139.1
|
| CTCF |
CD34+ hematopoietic stem cells-derived proerythroblasts |
adult bone marrow |
Permissive
|
Homo sapiens |
GSE36985
...
|
MA0139.1
|
| CTCF |
HCT-116 (colon carcinoma) |
DNMT1KO |
Permissive
Robust
|
Homo sapiens |
GSE50610
...
|
MA0139.1
|
| CTCF |
HCT-116 (colon carcinoma) |
DNMT3BKO |
Permissive
Robust
|
Homo sapiens |
GSE50610
...
|
MA0139.1
|
| CTCF |
HCT-116 (colon carcinoma) |
No special treatment |
Permissive
Robust
|
Homo sapiens |
GSE50610
...
|
MA0139.1
|
| CTCF |
HCT-116 (colon carcinoma) |
DNMT1KO, DNMT3BKO |
Permissive
Robust
|
Homo sapiens |
GSE50610
...
|
MA0139.1
|
| CTCF |
K562 (myelogenous leukemia) |
5-aza-2’-deoxycytidine (decitabine; Sigma, A3656) dissolved in DMSO to 10mM. Drug was administered at 1uM daily for 3 days. Control K562 cells were mock treated with DMSO. |
Permissive
Robust
|
Homo sapiens |
GSE50610
...
|
MA0139.1
|
| CTCF |
K562 (myelogenous leukemia) |
none |
Permissive
Robust
|
Homo sapiens |
GSE50611
...
|
MA0139.1
|
| CTCF |
erythroid progenitors |
none |
Permissive
Robust
|
Homo sapiens |
GSE52637
...
|
MA0139.1
|
| CTCF |
T47D (invasive ductal carcinoma) |
unstimulated |
Permissive
Robust
|
Homo sapiens |
GSE53463
...
|
MA0139.1
|
| CTCF |
T47D (invasive ductal carcinoma) |
progestin R5020-stimulated |
Permissive
Robust
|
Homo sapiens |
GSE53463
...
|
MA0139.1
|
| CTCF |
BEAS-2B (bronchial epithelium) |
NiCl2 |
Permissive
Robust
|
Homo sapiens |
GSE56051
...
|
MA0139.1
|
| CTCF |
liver |
Taf4-/- |
Permissive
Robust
|
Mus musculus |
GSE57807
...
|
MA0139.1
|
| CTCF |
Th1-cells |
FACS sorted naive CD4+T cells cultured in vitro for 7 days under Th1 condition |
Permissive
Robust
|
Mus musculus |
GSE60482
...
|
MA0139.1
|
| CTCF |
WEHI-231 (lymphoma ) |
TFII-I KD |
Permissive
Robust
|
Mus musculus |
GSE60917
...
|
MA0139.1
|
| CTCF |
E14.5 brain-derived neural progenitor cells |
Smchd1 null |
Permissive
Robust
|
Mus musculus |
GSE65748
...
|
MA0139.1
|
| CTCF |
E14.5 brain-derived neural progenitor cells |
non-silencing shRNA |
Permissive
Robust
|
Mus musculus |
GSE65748
...
|
MA0139.1
|
| CTCF |
dermal fibroblasts |
Xist deletion |
Permissive
Robust
|
Mus musculus |
GSE67516
...
|
MA0139.1
|
| CTCF |
embryonic fibroblasts |
AKT1 KO |
Permissive
Robust
|
Mus musculus |
GSE69798
...
|
MA0139.1
|
| CTCF |
226LDM (normal breast luminal cells) |
untreated |
Permissive
Robust
|
Homo sapiens |
GSE102237
...
|
MA0139.1
|
| CTCF |
226LDM (normal breast luminal cells) |
hydroxyurea and nocodazole |
Permissive
Robust
|
Homo sapiens |
GSE102237
...
|
MA0139.1
|
| CTCF |
brown preadipocytes |
Pparg-flox/flox |
Permissive
Robust
|
Mus musculus |
GSE74189
...
|
MA0139.1
|
| CTCF |
brown preadipocytes |
Pparg-flox/flox |
Permissive
Robust
|
Mus musculus |
GSE74189
...
|
MA0139.1
|
| CTCF |
brown preadipocytes |
Pparg-flox/flox |
Permissive
Robust
|
Mus musculus |
GSE74189
...
|
MA0139.1
|
| CTCF |
brown adipocytes |
Pparg-flox/flox |
Permissive
Robust
|
Mus musculus |
GSE74189
...
|
MA0139.1
|
| CTCF |
E13.5 embryonic fibroblasts |
WT; 10d resting |
Permissive
Robust
|
Mus musculus |
GSE76303
...
|
MA0139.1
|
| CTCF |
E13.5 embryonic fibroblasts |
WT; 10d resting |
Permissive
Robust
|
Mus musculus |
GSE76303
...
|
MA0139.1
|
| CTCF |
E13.5 embryonic fibroblasts |
Ctcf(fl/fl); 4h Adeno-Cre and 10d resting |
Permissive
Robust
|
Mus musculus |
GSE76303
...
|
MA0139.1
|
| CTCF |
E13.5 embryonic fibroblasts |
Rosa26(CreER/+) Smc3(fl/-); 2-3d 4'hydroxytamoxifen and 10d resting |
Permissive
Robust
|
Mus musculus |
GSE76303
...
|
MA0139.1
|
| CTCF |
E13.5 embryonic fibroblasts |
Rosa26(CreER/+) Smc3(fl/-); 2-3d 4'hydroxytamoxifen and 10d resting |
Permissive
Robust
|
Mus musculus |
GSE76303
...
|
MA0139.1
|
| CTCF |
E13.5 embryonic fibroblasts |
Rosa26(CreER/+) Wapl(fl/-); 2-3d 4'hydroxytamoxifen and 10d resting |
Permissive
Robust
|
Mus musculus |
GSE76303
...
|
MA0139.1
|
| CTCF |
E13.5 embryonic fibroblasts |
Rosa26(CreER/+) Wapl(fl/-); 2-3d 4'hydroxytamoxifen and 10d resting |
Permissive
Robust
|
Mus musculus |
GSE76303
...
|
MA0139.1
|
| CTCF |
G1E-derived erythroid cells |
D_Brd2KO |
Permissive
Robust
|
Mus musculus |
GSE80527
...
|
MA0139.1
|
| CTCF |
G1E-derived erythroid cells |
C8_Brd2KO |
Permissive
Robust
|
Mus musculus |
GSE80527
...
|
MA0139.1
|
| CTCF |
spleen B-cells |
activated |
Permissive
Robust
|
Mus musculus |
GSE82144
...
|
MA0139.1
|
| CTCF |
spleen B-cells |
resting |
Permissive
Robust
|
Mus musculus |
GSE82144
...
|
MA0139.1
|
| CTCF |
epidermal keratinocytes |
undifferentiated |
Permissive
Robust
|
Homo sapiens |
GSE84657
...
|
MA0139.1
|
| CTCF |
epidermal keratinocytes |
day3 of differentiation |
Permissive
Robust
|
Homo sapiens |
GSE84657
...
|
MA0139.1
|
| CTCF |
epidermal keratinocytes |
day6 of differentiation |
Permissive
Robust
|
Homo sapiens |
GSE84657
...
|
MA0139.1
|
| CTCF |
MCF7 (Invasive ductal breast carcinoma) |
control; 100 nM 17-beta-estradiol for 0h |
Permissive
Robust
|
Homo sapiens |
GSE85106
...
|
MA0139.1
|
| CTCF |
MCF7 (Invasive ductal breast carcinoma) |
100 nM 17-beta-estradiol for 45 min |
Permissive
Robust
|
Homo sapiens |
GSE85106
...
|
MA0139.1
|
| CTCF |
MCF7 (Invasive ductal breast carcinoma) |
100 nM 17-beta-estradiol for 3h |
Permissive
|
Homo sapiens |
GSE85106
...
|
MA0139.1
|
| CTCF |
V6.5 (embryonic stem cells) |
2i/LIF conditions |
Permissive
Robust
|
Mus musculus |
GSE85185
...
|
MA0139.1
|
| CTCF |
V6.5 (embryonic stem cells) |
standard serum/LIF conditions |
Permissive
Robust
|
Mus musculus |
GSE85185
...
|
MA0139.1
|
| CTCF |
retina |
p107 minus minus MDMXTg |
Permissive
Robust
|
Mus musculus |
GSE87037
...
|
MA0139.1
|
| CTCF |
CD4+ Th1 |
high IL-2 |
Permissive
Robust
|
Mus musculus |
GSE88857
...
|
MA0139.1
|
| CTCF |
CD4+ Th1 |
low IL-2 |
Permissive
Robust
|
Mus musculus |
GSE88857
...
|
MA0139.1
|
| CTCF |
CD4+ Th1 |
low IL-2 + aKG |
Permissive
Robust
|
Mus musculus |
GSE88857
...
|
MA0139.1
|
| CTCF |
JM8.N4 (embryonic stem cells) |
Rad21-SNAPf-V5 |
Permissive
Robust
|
Mus musculus |
GSE90994
...
|
MA0139.1
|
| CTCF |
mammary gland |
delAB mutant |
Permissive
Robust
|
Mus musculus |
GSE92587
...
|
MA0139.1
|
| CTCF |
mammary gland |
delC mutant |
Permissive
Robust
|
Mus musculus |
GSE92587
...
|
MA0139.1
|
| CTCF |
mammary gland |
delE mutant |
Permissive
Robust
|
Mus musculus |
GSE92587
...
|
MA0139.1
|
| CTCF |
mammary gland |
delCDE mutant |
Permissive
Robust
|
Mus musculus |
GSE92587
...
|
MA0139.1
|
| CTCF |
mammary gland |
delD mutant |
Permissive
Robust
|
Mus musculus |
GSE92587
...
|
MA0139.1
|
| CTCF |
mammary gland |
delA mutant |
Permissive
Robust
|
Mus musculus |
GSE92591
...
|
MA0139.1
|
| CTCF |
mammary gland |
delC mutant |
Permissive
Robust
|
Mus musculus |
GSE92591
...
|
MA0139.1
|
| CTCF |
mammary gland |
delB mutant |
Permissive
Robust
|
Mus musculus |
GSE92591
...
|
MA0139.1
|
| CTCF |
mammary gland |
delD mutant |
Permissive
Robust
|
Mus musculus |
GSE92591
...
|
MA0139.1
|
| CTCF |
K562 (myelogenous leukemia) |
+DOX 3 days, mutant CTCF |
Permissive
Robust
|
Homo sapiens |
GSE92879
...
|
MA0139.1
|
| CTCF |
liver |
tamoxifen |
Permissive
Robust
|
Mus musculus |
GSE93431
...
|
MA0139.1
|
| CTCF |
liver |
tamoxifen |
Permissive
Robust
|
Mus musculus |
GSE93431
...
|
MA0139.1
|
| CTCF |
spleen-derived Ter119+ erythroid cells |
Phenylhydrazine |
Permissive
Robust
|
Mus musculus |
GSE97869
...
|
MA0139.1
|
| CTCF |
spleen-derived Ter119+ erythroid cells |
D29 mutant of CTCF; Phenylhydrazine |
Permissive
Robust
|
Mus musculus |
GSE97869
...
|
MA0139.1
|
| CTCF |
spleen-derived Ter119+ erythroid cells |
D38_D39 mutant of CTCF; Phenylhydrazine |
Permissive
Robust
|
Mus musculus |
GSE97869
...
|
MA0139.1
|
| CTCF |
spleen-derived Ter119+ erythroid cells |
D38 mutant of CTCF; Phenylhydrazine |
Permissive
Robust
|
Mus musculus |
GSE97869
...
|
MA0139.1
|
| CTCF |
spleen-derived Ter119+ erythroid cells |
D39 mutant of CTCF; Phenylhydrazine |
Permissive
Robust
|
Mus musculus |
GSE97869
...
|
MA0139.1
|
| CTCF |
E14TG2A (embryonic stem cells) |
washoff2days |
Permissive
Robust
|
Mus musculus |
GSE98671
...
|
MA0139.1
|
| CTCF |
cerebral cortex |
CK-KO |
Permissive
Robust
|
Mus musculus |
GSE99363
...
|
MA0139.1
|
| CTCF |
cerebral cortex |
CK-KO |
Permissive
Robust
|
Mus musculus |
GSE99363
...
|
MA0139.1
|
| CTCF |
cerebral cortex |
CK-KO |
Permissive
Robust
|
Mus musculus |
GSE99363
...
|
MA0139.1
|
| CTCF |
cerebral cortex |
CK-KO |
Permissive
Robust
|
Mus musculus |
GSE99363
...
|
MA0139.1
|
| CTCF |
A549 (lung carcinoma) |
100nM dexamethasone (CHEBI:41879) for 3 hour |
Permissive
Robust
|
Homo sapiens |
ENCSR851SOK
|
MA0139.1
|
| CTCF |
A549 (lung carcinoma) |
100nM dexamethasone (CHEBI:41879) for 6 hour |
Permissive
Robust
|
Homo sapiens |
ENCSR287UXS
|
MA0139.1
|
| CTCF |
A549 (lung carcinoma) |
100nM dexamethasone (CHEBI:41879) for 4 hour |
Permissive
Robust
|
Homo sapiens |
ENCSR130TQM
|
MA0139.1
|
| CTCF |
A549 (lung carcinoma) |
1 h with 100 nM Dexamethasone (Myers) |
Permissive
Robust
|
Homo sapiens |
ENCSR249JOH
|
MA0139.1
|
| CTCF |
bipolar neuron |
0.5 μg/mL doxycycline hyclate (CHEBI:34730) for 4 day |
Permissive
Robust
|
Homo sapiens |
ENCSR619IUE
|
MA0139.1
|
| CTCF |
A549 (lung carcinoma) |
100nM dexamethasone (CHEBI:41879) for 10 hour |
Permissive
Robust
|
Homo sapiens |
ENCSR336VBV
|
MA0139.1
|
| CTCF |
A549 (lung carcinoma) |
100nM dexamethasone (CHEBI:41879) for 30 minute |
Permissive
Robust
|
Homo sapiens |
ENCSR553UWG
|
MA0139.1
|
| CTCF |
A549 (lung carcinoma) |
100nM dexamethasone (CHEBI:41879) for 7 hour |
Permissive
Robust
|
Homo sapiens |
ENCSR173IEA
|
MA0139.1
|
| CTCF |
A549 (lung carcinoma) |
100nM dexamethasone (CHEBI:41879) for 8 hour |
Permissive
Robust
|
Homo sapiens |
ENCSR432AXE
|
MA0139.1
|
| CTCF |
A549 (lung carcinoma) |
100nM dexamethasone (CHEBI:41879) for 2 hour |
Permissive
Robust
|
Homo sapiens |
ENCSR384KPP
|
MA0139.1
|
| CTCF |
A549 (lung carcinoma) |
100nM dexamethasone (CHEBI:41879) for 12 hour |
Permissive
Robust
|
Homo sapiens |
ENCSR414CQB
|
MA0139.1
|
| CTCF |
A549 (lung carcinoma) |
100nM dexamethasone (CHEBI:41879) for 5 hour |
Permissive
Robust
|
Homo sapiens |
ENCSR876UZD
|
MA0139.1
|
| CTCF |
HPC7 (haematopoietic multipotent progenitors) |
thrombopoietin 30 minutes |
Permissive
Robust
|
Mus musculus |
GSE100835
...
|
MA0139.1
|
| CTCF |
HPC7 (haematopoietic multipotent progenitors) |
serum-starved |
Permissive
Robust
|
Mus musculus |
GSE100835
...
|
MA0139.1
|
| CTCF |
E12.5 embryonic distal forelimb |
CD1 strain |
Permissive
Robust
|
Mus musculus |
GSE101714
...
|
MA0139.1
|
| CTCF |
E12.5 embryonic proximal forelimbs |
CD1 strain |
Permissive
Robust
|
Mus musculus |
GSE101714
...
|
MA0139.1
|
| CTCF |
E12.5 embryonic forelimbs and hindlimbs |
B6CBAF1 strain |
Permissive
Robust
|
Mus musculus |
GSE101714
...
|
MA0139.1
|
| CTCF |
E12.5 embryonic forelimbs and hindlimbs |
B6CBAF1 strain; delHoxd(8-13)d11lac |
Permissive
Robust
|
Mus musculus |
GSE101714
...
|
MA0139.1
|
| CTCF |
E12.5 embryonic forelimbs and hindlimbs |
B6CBAF1 strain; delHoxd(8-13)rXII |
Permissive
Robust
|
Mus musculus |
GSE101714
...
|
MA0139.1
|
| CTCF |
E12.5 embryonic forelimbs and hindlimbs |
B6CBAF1 strain; delHoxd(1-13)d9lac |
Permissive
Robust
|
Mus musculus |
GSE101714
...
|
MA0139.1
|
| CTCF |
E12.5 embryonic forelimbs and hindlimbs |
B6CBAF1 strain; delHoxd(attP-rel5)d9lac |
Permissive
Robust
|
Mus musculus |
GSE101714
...
|
MA0139.1
|
| CTCF |
CD34+ stem cells-derived erythroblasts |
Fetal |
Permissive
Robust
|
Homo sapiens |
GSE102184
...
|
MA0139.1
|
| CTCF |
CD34+ stem cells-derived erythroblasts |
Adult |
Permissive
Robust
|
Homo sapiens |
GSE102184
...
|
MA0139.1
|
| CTCF |
HeLa Kyoto (cervical adenocarcinoma) |
Wild type |
Permissive
Robust
|
Homo sapiens |
GSE102884
...
|
MA0139.1
|
| CTCF |
HeLa Kyoto (cervical adenocarcinoma) |
Wapl-depletion |
Permissive
Robust
|
Homo sapiens |
GSE102884
...
|
MA0139.1
|
| CTCF |
HeLa Kyoto (cervical adenocarcinoma) |
Pds5SA/B depletion |
Permissive
Robust
|
Homo sapiens |
GSE102884
...
|
MA0139.1
|
| CTCF |
HeLa Kyoto (cervical adenocarcinoma) |
Wapl/Pds5A/B depletion |
Permissive
Robust
|
Homo sapiens |
GSE102884
...
|
MA0139.1
|
| CTCF |
liver |
ZT22 (5AM); Wild type |
Permissive
Robust
|
Mus musculus |
GSE104129
...
|
MA0139.1
|
| CTCF |
liver |
ZT10 (5PM); Wild type |
Permissive
Robust
|
Mus musculus |
GSE104129
...
|
MA0139.1
|
| CTCF |
embryonic fibroblasts |
Firre KO |
Permissive
Robust
|
Mus musculus |
GSE104427
...
|
MA0139.1
|
| CTCF |
embryonic fibroblasts |
Firre transgene |
Permissive
Robust
|
Mus musculus |
GSE104427
...
|
MA0139.1
|
| CTCF |
HCT-116-RAD21-mAC |
500uM auxin (360 min) |
Permissive
Robust
|
Homo sapiens |
GSE104888
...
|
MA0139.1
|
| CTCF |
bone marrow-derived macrophages |
C57BL/6; 3 months; male |
Permissive
Robust
|
Mus musculus |
GSE107455
...
|
MA0139.1
|
| CTCF |
S2-DRSC (embryonic stem cells) |
strain: Oregon-R, genotype: wild type |
Permissive
Robust
|
Drosophila melanogaster |
ENCSR711UTK
|
MA0531.1
|
| CTCF |
S2-DRSC (embryonic stem cells) |
strain: Oregon-R, genotype: wild type |
Permissive
Robust
|
Drosophila melanogaster |
ENCSR918GXT
|
MA0531.1
|
| CTCF |
whole organism (development stage: prepupa) |
white prepupae stage |
Permissive
Robust
|
Drosophila melanogaster |
GSE24449
...
|
MA0531.1
|
| CTCF |
Kc167 (development stage: embryonic) |
20-HE 0 hrs |
Permissive
Robust
|
Drosophila melanogaster |
GSE30740
...
|
MA0531.1
|
| CTCF |
Kc167 (development stage: embryonic) |
20-HE 3 hrs |
Permissive
Robust
|
Drosophila melanogaster |
GSE30740
...
|
MA0531.1
|
| CTCF |
Kc167 (development stage: embryonic) |
20-HE 48 hrs |
Permissive
Robust
|
Drosophila melanogaster |
GSE30740
...
|
MA0531.1
|
| CTCF |
Kc167 (development stage: embryonic) |
Interphase |
Permissive
Robust
|
Drosophila melanogaster |
GSE32584
...
|
MA0531.1
|
| CTCF |
Kc167 (development stage: embryonic) |
Mitosis |
Permissive
Robust
|
Drosophila melanogaster |
GSE32584
...
|
MA0531.1
|
| CTCF |
S2-DRSC (embryonic stem cells) |
3AB treated |
Permissive
Robust
|
Drosophila melanogaster |
GSE41354
...
|
MA0531.1
|
| CTCF |
5-13 h embryo |
parasegment 7 |
Permissive
Robust
|
Drosophila melanogaster |
GSE55257
...
|
MA0531.1
|
| CTCF |
5-13 h embryo |
whole embryo |
Permissive
Robust
|
Drosophila melanogaster |
GSE55257
...
|
MA0531.1
|
| CTCF |
whole organism (development stage: wandering third instar larva) |
Eye-Antennal discs |
Permissive
Robust
|
Drosophila melanogaster |
GSE59078
...
|
MA0531.1
|
| CTCF |
Kc167 (development stage: embryonic) |
normal temperature |
Permissive
Robust
|
Drosophila melanogaster |
GSE62904
...
|
MA0531.1
|
| CTCF |
Kc167 (development stage: embryonic) |
heat shock |
Permissive
Robust
|
Drosophila melanogaster |
GSE62904
...
|
MA0531.1
|
| CTCF |
Kc167 (development stage: embryonic) |
treatment with decapentaplegic (DPP) |
Permissive
Robust
|
Drosophila melanogaster |
GSE68654
...
|
MA0531.1
|
| CTCF |
S2 (Schneider 2) |
100mM CuSO4 24 h after seading cells |
Permissive
Robust
|
Drosophila melanogaster |
GSE96581
...
|
MA0531.1
|
| CTCF |
THP-1 (acute monocytic leukemia) |
Treatment: IFNb treated 6hr, eGFP(EP mRNA) |
Permissive
Robust
|
Homo sapiens |
GSE103477
...
|
MA0139.1
|
| CTCF |
THP-1 (acute monocytic leukemia) |
Treatment: IFNb treated 6hr, IAV NS1(EP mRNA) |
Permissive
Robust
|
Homo sapiens |
GSE103477
...
|
MA0139.1
|
| CTCF |
THP-1 (acute monocytic leukemia) |
Treatment: untreated, eGFP(EP mRNA), siCtrl(siRNA) |
Permissive
Robust
|
Homo sapiens |
GSE103477
...
|
MA0139.1
|
| CTCF |
THP-1 (acute monocytic leukemia) |
Treatment: Pam3csk4 treated 4hr, eGFP(EP mRNA), siCtrl(siRNA) |
Permissive
Robust
|
Homo sapiens |
GSE103477
...
|
MA0139.1
|
| CTCF |
THP-1 (acute monocytic leukemia) |
Treatment: Pam3csk4 treated 0hr, IAV NS1(EP mRNA), siCtrl(siRNA) |
Permissive
Robust
|
Homo sapiens |
GSE103477
...
|
MA0139.1
|
| CTCF |
THP-1 (acute monocytic leukemia) |
Treatment: Pam3csk4 treated 4hr, IAV NS1(EP mRNA), siCtrl(siRNA) |
Permissive
Robust
|
Homo sapiens |
GSE103477
...
|
MA0139.1
|
| CTCF |
THP-1 (acute monocytic leukemia) |
Treatment: Pam3csk4 treated 7hr+Flavopiridol 3hr, IAV NS1(EP mRNA), siCtrl(siRNA) |
Permissive
Robust
|
Homo sapiens |
GSE103477
...
|
MA0139.1
|
| CTCF |
THP-1 (acute monocytic leukemia) |
Treatment: Pam3csk4 treated 4hr, eGFP(EP mRNA), siNIPBL(siRNA) |
Permissive
Robust
|
Homo sapiens |
GSE103477
...
|
MA0139.1
|
| CTCF |
THP-1 (acute monocytic leukemia) |
Treatment: Pam3csk4 treated 4hr, IAV NS1(EP mRNA), siNIPBL(siRNA) |
Permissive
Robust
|
Homo sapiens |
GSE103477
...
|
MA0139.1
|
| CTCF |
THP-1 (acute monocytic leukemia) |
Treatment: Pam3csk4 treated 7hr+Flavopiridol 3hr, IAV NS1(EP mRNA), siNIPBL(siRNA) |
Permissive
Robust
|
Homo sapiens |
GSE103477
...
|
MA0139.1
|
| CTCF |
THP-1 (acute monocytic leukemia) |
Treatment: Pam3csk4 treated 4hr, eGFP(EP mRNA), siWAPL(siRNA) |
Permissive
Robust
|
Homo sapiens |
GSE103477
...
|
MA0139.1
|
| CTCF |
THP-1 (acute monocytic leukemia) |
Treatment: Pam3csk4 treated 4hr, IAV NS1(EP mRNA), siWAPL(siRNA) |
Permissive
Robust
|
Homo sapiens |
GSE103477
...
|
MA0139.1
|
| CTCF |
THP-1 (acute monocytic leukemia) |
Treatment: Pam3csk4 treated 7hr+Flavopiridol 3hr, IAV NS1(EP mRNA), siWAPL(siRNA) |
Permissive
Robust
|
Homo sapiens |
GSE103477
...
|
MA0139.1
|
| CTCF |
THP-1 (acute monocytic leukemia) |
Treatment: untreated |
Permissive
Robust
|
Homo sapiens |
GSE103477
...
|
MA0139.1
|
| CTCF |
THP-1 (acute monocytic leukemia) |
Treatment: Pam3csk4 treated 20min |
Permissive
Robust
|
Homo sapiens |
GSE103477
...
|
MA0139.1
|
| CTCF |
THP-1 (acute monocytic leukemia) |
Pam3csk4 treated (025m) |
Permissive
Robust
|
Homo sapiens |
GSE103477
...
|
MA0139.1
|
| CTCF |
THP-1 (acute monocytic leukemia) |
Treatment: Pam3csk4 treated 30min |
Permissive
Robust
|
Homo sapiens |
GSE103477
...
|
MA0139.1
|
| CTCF |
THP-1 (acute monocytic leukemia) |
Treatment: Pam3csk4 treated 45min |
Permissive
Robust
|
Homo sapiens |
GSE103477
...
|
MA0139.1
|
| CTCF |
THP-1 (acute monocytic leukemia) |
Treatment: Pam3csk4 treated 60min |
Permissive
Robust
|
Homo sapiens |
GSE103477
...
|
MA0139.1
|
| CTCF |
THP-1 (acute monocytic leukemia) |
Treatment: Pam3csk4 treated 120min |
Permissive
Robust
|
Homo sapiens |
GSE103477
...
|
MA0139.1
|
| CTCF |
THP-1 (acute monocytic leukemia) |
Treatment: Pam3csk4 treated 150min + Flavopiridol 30min |
Permissive
Robust
|
Homo sapiens |
GSE103477
...
|
MA0139.1
|
| CTCF |
THP-1 (acute monocytic leukemia) |
Treatment: Pam3csk4 treated 180min + Flavopiridol 60min |
Permissive
Robust
|
Homo sapiens |
GSE103477
...
|
MA0139.1
|
| CTCF |
THP-1 (acute monocytic leukemia) |
Treatment: Pam3csk4 treated 360min + Flavopiridol 240min |
Permissive
Robust
|
Homo sapiens |
GSE103477
...
|
MA0139.1
|
| CTCF |
THP-1 (acute monocytic leukemia) |
Treatment: Flavopiridol 240min |
Permissive
Robust
|
Homo sapiens |
GSE103477
...
|
MA0139.1
|
| CTCF |
THP-1 (acute monocytic leukemia) |
Treatment: untreated |
Permissive
Robust
|
Homo sapiens |
GSE103477
...
|
MA0139.1
|
| CTCF |
THP-1 (acute monocytic leukemia) |
Treatment: dexamethasone 6hr |
Permissive
Robust
|
Homo sapiens |
GSE103477
...
|
MA0139.1
|
| CTCF |
MDM(monocyte derived macrophages) |
Treatment: mock infected 6hr |
Permissive
Robust
|
Homo sapiens |
GSE103477
...
|
MA0139.1
|
| CTCF |
MDM(monocyte derived macrophages) |
Treatment: H5N1 IAV infected 6hr |
Permissive
Robust
|
Homo sapiens |
GSE103477
...
|
MA0139.1
|
| CTCF |
MDM(monocyte derived macrophages) |
Treatment: H5N1-dNS1 IAV infected 6hr |
Permissive
Robust
|
Homo sapiens |
GSE103477
...
|
MA0139.1
|
| CTCF |
MDM(monocyte derived macrophages) |
Treatment: IFNb treated 6hr |
Permissive
Robust
|
Homo sapiens |
GSE103477
...
|
MA0139.1
|
| CTCF |
WA09 (embryonic stem cells) |
Treatment: under normal conditions |
Permissive
Robust
|
Homo sapiens |
GSE105028
...
|
MA0139.1
|
| CTCF |
WA09 (embryonic stem cells) |
Treatment: under heat shock conditions |
Permissive
Robust
|
Homo sapiens |
GSE105028
...
|
MA0139.1
|
| CTCF |
WA09 (embryonic stem cells) |
Treatment: under normal conditions |
Permissive
Robust
|
Homo sapiens |
GSE105028
...
|
MA0139.1
|
| CTCF |
WA09 (embryonic stem cells) |
Treatment: under heat shock conditions |
Permissive
Robust
|
Homo sapiens |
GSE105028
...
|
MA0139.1
|
| CTCF |
HeLa (cervical adenocarcinoma) |
Plasmids: pGK-dCas9-SunTag (Addgene #100943) + pEF1a-NLS-scFvGCN4-DNMT3A (Addgene #100941) + pEf1a-SHB_1-gRNA-GFP |
Permissive
Robust
|
Homo sapiens |
GSE107607
...
|
MA0139.1
|
| CTCF |
HeLa (cervical adenocarcinoma) |
Plasmids: GK-dCas9-SunTag (Addgene #100943) + pEF1a-NLS-scFvGCN4-DNMT3A (Addgene #100941) + pEf1a-MIR152_3-gRNA-GFP |
Permissive
Robust
|
Homo sapiens |
GSE107607
...
|
MA0139.1
|
| CTCF |
HeLa (cervical adenocarcinoma) |
Plasmids: pGK-dCas9-SunTag (Addgene #100943) + pEF1a-NLS-scFvGCN4-DNMT3A (Addgene #100941) + pEf1a-CCDC85C_3-gRNA-GFP |
Permissive
Robust
|
Homo sapiens |
GSE107607
...
|
MA0139.1
|
| CTCF |
HeLa (cervical adenocarcinoma) |
Plasmids: pGK-dCas9-SunTag (Addgene #100943) + pEF1a-NLS-scFvGCN4-DNMT3A (Addgene #100941) + pEf1a-MIR152-gRNA-GFP |
Permissive
Robust
|
Homo sapiens |
GSE107607
...
|
MA0139.1
|
| CTCF |
HeLa S3 (cervical adenocarcinoma) |
treatment: no block with TSA CellPopulation:synchronized |
Permissive
Robust
|
Homo sapiens |
GSE108173
...
|
MA0139.1
|
| CTCF |
HeLa S3 (cervical adenocarcinoma) |
treatment: no block with TSA CellPopulation:synchronized |
Permissive
Robust
|
Homo sapiens |
GSE108173
...
|
MA0139.1
|
| CTCF |
HeLa S3 (cervical adenocarcinoma) |
treatment: no block with TSA CellPopulation:unsynchronized |
Permissive
Robust
|
Homo sapiens |
GSE108173
...
|
MA0139.1
|
| CTCF |
HeLa S3 (cervical adenocarcinoma) |
treatment: no block with TSA CellPopulation:unsynchronized |
Permissive
Robust
|
Homo sapiens |
GSE108173
...
|
MA0139.1
|
| CTCF |
LUHMES (lund human mesencephalic cells) |
Sex: female Passages: 3-10 Stage: neural progenitor cells, undifferentiated Treatment: Prior to differentiation, cells were seeded at 3.5 x 10^6 per T75 flask containing complete growth medium and incubated at 37 °C for 24 hr |
Permissive
Robust
|
Homo sapiens |
GSE109706
...
|
MA0139.1
|
| CTCF |
LUHMES (lund human mesencephalic cells) |
Sex: female Passages: 3-10 Stage: dopaminergic neurons, differentiated Treatment: For induction of differentiation, culture medium was changed to freshly prepare DMEM:F12 with 2 mM L-glutamine, 1X N-2, 1 mM cAMP (Carbosynth, Cat # ND07996), 1 mg/mL tetracycline (Sigma, Cat # T7660), and 2 ng/mL glial cell line-derived neurotrophic factor (GDNF) (Sigma, Cat # G1777) |
Permissive
Robust
|
Homo sapiens |
GSE109706
...
|
MA0139.1
|
| CTCF |
MDM(monocyte derived macrophages) |
Treatment: mock infected, time post infection 24 hr |
Permissive
Robust
|
Homo sapiens |
GSE118305
...
|
MA0139.1
|
| CTCF |
MDM(monocyte derived macrophages) |
Treatment: ZIKV-bystander, time post infection 24 hr ViralStrain: ZIKV-FSS13025 |
Permissive
Robust
|
Homo sapiens |
GSE118305
...
|
MA0139.1
|
| CTCF |
MDM(monocyte derived macrophages) |
Treatment: ZIKV-bystander, time post infection 24 hr ViralStrain: ZIKV-FSS13025 |
Permissive
Robust
|
Homo sapiens |
GSE118305
...
|
MA0139.1
|
| CTCF |
ID00014 (lymphoblastoid cell, DiGeorge syndrome) |
Genotype: 22q11 deletion Cell type: lymphoblastoid cell Age: 34 |
Permissive
Robust
|
Homo sapiens |
GSE76922
...
|
MA0139.1
|
| CTCF |
ID00015 (lymphoblastoid cell) |
Genotype: wildtype Cell type: lymphoblastoid cell |
Permissive
Robust
|
Homo sapiens |
GSE76922
...
|
MA0139.1
|
| CTCF |
ID00014 (lymphoblastoid cell, DiGeorge syndrome) |
Genotype: 22q11 deletion Cell type: lymphoblastoid cell Age: 11 |
Permissive
Robust
|
Homo sapiens |
GSE76922
...
|
MA0139.1
|
| CTCF |
MIA PaCa-2 (pancreatic ductal adenocarcinoma) |
Treatment: none |
Permissive
Robust
|
Homo sapiens |
GSE88734
...
|
MA0139.1
|
| CTCF |
HUES64 (embryonic stem cells) |
Genotype: wildtype |
Permissive
Robust
|
Homo sapiens |
GSE97394
...
|
MA0139.1
|
| CTCF |
HUES64 (embryonic stem cells) |
Genotype: CTCF knockout |
Permissive
Robust
|
Homo sapiens |
GSE97394
...
|
MA0139.1
|
| CTCF |
CH12 (lymphoma) |
Treatment: no Genotype: wildtype |
Permissive
Robust
|
Mus musculus |
GSE98119
...
|
MA0139.1
|
| CTCF |
CH12 (lymphoma) |
Treatment: no Genotype: CTCFmZF9to11 |
Permissive
Robust
|
Mus musculus |
GSE98119
...
|
MA0139.1
|
| CTCF |
ES cells (plasmacytomas) |
Treatment: no Genotype: wildtype |
Permissive
Robust
|
Mus musculus |
GSE98119
...
|
MA0139.1
|
| CTCF |
CH12 (lymphoma) |
Treatment: no Genotype: SA deletion |
Permissive
Robust
|
Mus musculus |
GSE98119
...
|
MA0139.1
|
| CTCF |
activated B-cells |
Treatment: activated, 30hr, UH no treated Genotype: wildtype |
Permissive
Robust
|
Mus musculus |
GSE98119
...
|
MA0139.1
|
| CTCF |
liver |
Sex: male Strain: Crl:CD1(ICR) (Charles River, strain code #022) |
Permissive
Robust
|
Mus musculus |
GSE102997
...
|
MA0139.1
|
| CTCF |
NIH 3T3 (embryonic fibroblasts) |
Stable integrate: N/A Treatment: Cells were kept in DMEM supplemented with 2 ug/ml Doxycycline for 48 hrs |
Permissive
Robust
|
Mus musculus |
GSE103198
...
|
MA0139.1
|
| CTCF |
NIH 3T3 (embryonic fibroblasts) |
Stable integrate: pBI-EGFP-FLAG-mCtcfl and pTA-N Treatment: Cells were kept in DMEM supplemented with 2 ug/ml Doxycycline for 48 hrs |
Permissive
Robust
|
Mus musculus |
GSE103198
...
|
MA0139.1
|
| CTCF |
P19 (embryonic carcinoma) |
Treatment: Cells were kept in DMEM supplemented with 2 ug/ml Doxycycline for 48 hrs |
Permissive
Robust
|
Mus musculus |
GSE103198
...
|
MA0139.1
|
| CTCF |
flow sorted pre-B cells |
Genotype: B220+CD19+CD43-CD25+IgM- Age: 3 months Tissue: bone marrow Strain: C57BL/6 |
Permissive
Robust
|
Mus musculus |
GSE109671
...
|
MA0139.1
|
| CTCF |
flow sorted pre-B cells |
Genotype: B220+CD19+CD43-CD25+IgM- Age: 18 -22 months Tissue: bone marrow Strain: C57BL/6 |
Permissive
Robust
|
Mus musculus |
GSE109671
...
|
MA0139.1
|
| CTCF |
induced pluripotent stem cells |
Cell line: Rod_I_Y-8602 Strain: C57BL/6 |
Permissive
Robust
|
Mus musculus |
GSE109712
...
|
MA0139.1
|
| CTCF |
induced pluripotent stem cells |
Cell line: Bipo_I_Y-rM0401 Strain: C57BL/6 |
Permissive
Robust
|
Mus musculus |
GSE109712
...
|
MA0139.1
|
| CTCF |
induced pluripotent stem cells |
Cell line: Bipo_I_Y-rM0405 Strain: C57BL/6 |
Permissive
Robust
|
Mus musculus |
GSE109712
...
|
MA0139.1
|
| CTCF |
induced pluripotent stem cells |
Cell line: Bipo_I_Y-208.03 Strain: C57BL/6 |
Permissive
Robust
|
Mus musculus |
GSE109712
...
|
MA0139.1
|
| CTCF |
induced pluripotent stem cells |
Cell line: Bipo_I_Y-208.04 Strain: C57BL/6 |
Permissive
Robust
|
Mus musculus |
GSE109712
...
|
MA0139.1
|
| CTCF |
induced pluripotent stem cells |
Cell line: Mull_I_Y-207.11 Strain: C57BL/6 |
Permissive
Robust
|
Mus musculus |
GSE109712
...
|
MA0139.1
|
| CTCF |
induced pluripotent stem cells |
Cell line: Mull_M_Y-rCr33.01 Strain: C57BL/6 |
Permissive
Robust
|
Mus musculus |
GSE109712
...
|
MA0139.1
|
| CTCF |
induced pluripotent stem cells |
Cell line: Mull_M_Y-rCr33.04 Strain: C57BL/6 |
Permissive
Robust
|
Mus musculus |
GSE109712
...
|
MA0139.1
|
| CTCF |
induced pluripotent stem cells |
Cell line: Mull_M_Y-Cr143.01 Strain: C57BL/6 |
Permissive
Robust
|
Mus musculus |
GSE109712
...
|
MA0139.1
|
| CTCF |
induced pluripotent stem cells |
Cell line: Mull_M_Y-263.08 Strain: C57BL/6 |
Permissive
Robust
|
Mus musculus |
GSE109712
...
|
MA0139.1
|
| CTCF |
induced pluripotent stem cells |
Cell line: Amac_M_Y-30.02 Strain: C57BL/6 |
Permissive
Robust
|
Mus musculus |
GSE109712
...
|
MA0139.1
|
| CTCF |
induced pluripotent stem cells |
Cell line: Cone_I_Y-209.11 Strain: C57BL/6 |
Permissive
Robust
|
Mus musculus |
GSE109712
...
|
MA0139.1
|
| CTCF |
induced pluripotent stem cells |
Cell line: Cone_I_Y-209.12 Strain: C57BL/6 |
Permissive
Robust
|
Mus musculus |
GSE109712
...
|
MA0139.1
|
| CTCF |
induced pluripotent stem cells |
Cell line: Cone_I_Y-209.13 Strain: C57BL/6 |
Permissive
Robust
|
Mus musculus |
GSE109712
...
|
MA0139.1
|
| CTCF |
induced pluripotent stem cells |
Cell line: Cone_M_Y-257.03 Strain: C57BL/6 |
Permissive
Robust
|
Mus musculus |
GSE109712
...
|
MA0139.1
|
| CTCF |
induced pluripotent stem cells |
Cell line: RodFibr_F_Y-FNR07 Strain: C57BL/6 |
Permissive
Robust
|
Mus musculus |
GSE109712
...
|
MA0139.1
|
| CTCF |
induced pluripotent stem cells |
Cell line: Bipo_I_N-rM0408 Strain: C57BL/6 |
Permissive
Robust
|
Mus musculus |
GSE109712
...
|
MA0139.1
|
| CTCF |
induced pluripotent stem cells |
Cell line: MullFibr_F_N-FCR01 Strain: C57BL/6 |
Permissive
Robust
|
Mus musculus |
GSE109712
...
|
MA0139.1
|
| CTCF |
induced pluripotent stem cells |
Cell line: MullFibr_F_N-FCR02 Strain: C57BL/6 |
Permissive
Robust
|
Mus musculus |
GSE109712
...
|
MA0139.1
|
| CTCF |
induced pluripotent stem cells |
Cell line: AmacFibr_F_N-fG140.02 Strain: C57BL/6 |
Permissive
Robust
|
Mus musculus |
GSE109712
...
|
MA0139.1
|
| CTCF |
induced pluripotent stem cells |
Cell line: Mull_M_N-rCr33.05 Strain: C57BL/6 |
Permissive
Robust
|
Mus musculus |
GSE109712
...
|
MA0139.1
|
| CTCF |
induced pluripotent stem cells |
Cell line: Mull_M_N-rCr263.4 Strain: C57BL/6 |
Permissive
Robust
|
Mus musculus |
GSE109712
...
|
MA0139.1
|
| CTCF |
induced pluripotent stem cells |
Cell line: Cone_I_N-rCh209.04 Strain: C57BL/6 |
Permissive
Robust
|
Mus musculus |
GSE109712
...
|
MA0139.1
|
| CTCF |
induced pluripotent stem cells |
Cell line: Mull_M_N-rCr143.02 Strain: C57BL/6 |
Permissive
Robust
|
Mus musculus |
GSE109712
...
|
MA0139.1
|
| CTCF |
induced pluripotent stem cells |
Cell line: Amac_I_N-rG79.04 Strain: C57BL/6 |
Permissive
Robust
|
Mus musculus |
GSE109712
...
|
MA0139.1
|
| CTCF |
induced pluripotent stem cells |
Cell line: Cone_M_N-rCh257.4 Strain: C57BL/6 |
Permissive
Robust
|
Mus musculus |
GSE109712
...
|
MA0139.1
|
| CTCF |
NRL-GFP sorted Rod cell postnatal day 21 |
Cell line: CTCF-NRL-Rod_M_N-P21 Strain: C57BL/6 |
Permissive
Robust
|
Mus musculus |
GSE109712
...
|
MA0139.1
|
| CTCF |
NRL-GFP sorted Rod cell postnatal day 6 |
Cell line: CTCF-NRL-Rod_M_N-P6 Strain: C57BL/6 |
Permissive
Robust
|
Mus musculus |
GSE109712
...
|
MA0139.1
|
| CTCF |
pro-B cells |
Strain: C57BL/6 Genotype: RAG1-/- Treatment: cultured with IL7 |
Permissive
Robust
|
Mus musculus |
GSE109909
...
|
MA0139.1
|
| CTCF |
pre-B cells |
Strain: C57BL/6 Genotype: RAG1-/- u+ |
Permissive
Robust
|
Mus musculus |
GSE109909
...
|
MA0139.1
|
| CTCF |
GM17942 (lymphoblastoid cell) |
Genotype: 22q11 deletion Cell type: lymphoblastoid cell Age: 6 |
Permissive
Robust
|
Homo sapiens |
GSE76922
...
|
MA0139.1
|
| CTCF |
GM12878 (female B-cells lymphoblastoid cell line) |
Genotype: wildtype Cell type: lymphoblastoid cell Age: no |
Permissive
Robust
|
Homo sapiens |
GSE76922
...
|
MA0139.1
|
| CTCF |
MC3T3-E1 (preosteoblasts) |
Passage: 28 -31 Day:0 Strain: C57BL/6 Celltype: preosteoblast |
Permissive
Robust
|
Mus musculus |
GSE55045
...
|
MA0139.1
|
| CTCF |
MC3T3-E1 (preosteoblasts) |
Passage: 28 -31 Day:9 Strain: C57BL/6 Celltype: matrix-depositing osteoblast |
Permissive
Robust
|
Mus musculus |
GSE55045
...
|
MA0139.1
|
| CTCF |
MC3T3-E1 (preosteoblasts) |
Passage: 28 -31 Day:28 Strain: C57BL/6 Celltype: mineralizing osteoblast |
Permissive
Robust
|
Mus musculus |
GSE55045
...
|
MA0139.1
|
| CTCF |
Th2-cells |
Treatment: C57BL/6 |
Permissive
Robust
|
Mus musculus |
GSE66343
...
|
MA0139.1
|
| CTCF |
EL4 (lymphoma) |
Treatment: C57BL/6 Genotype: wildtype |
Permissive
Robust
|
Mus musculus |
GSE66343
...
|
MA0139.1
|
| CTCF |
EL4 (lymphoma) |
Treatment: C57BL/6 Genotype: CTCF-motif knockout Treatment: Genome Editing was carried out by CRISPR/Cas9 system |
Permissive
Robust
|
Mus musculus |
GSE66343
...
|
MA0139.1
|
| CTCF |
ES-E14 (E14, embryonic stem cells) |
Genotype: Mll3-/- Mll4-/- (double knockout) dead Cas9 protein (dCas9) without MLL3SET domain |
Permissive
Robust
|
Mus musculus |
GSE74055
...
|
MA0139.1
|
| CTCF |
ES-E14 (E14, embryonic stem cells) |
Genotype: Mll3-/- Mll4-/- (double knockout), dCas9-MLL3SET fusion protein |
Permissive
Robust
|
Mus musculus |
GSE74055
...
|
MA0139.1
|
| CTCF |
nephron progenitors |
Genotype: wildtype Age: E16.5 (developing stage) Strain: CFW |
Permissive
Robust
|
Mus musculus |
GSE90016
...
|
MA0139.1
|
| CTCF |
nephron progenitors |
Genotype: wildtype Age: E16.5 (developing stage) Strain: CFW |
Permissive
Robust
|
Mus musculus |
GSE90016
...
|
MA0139.1
|
| CTCF |
bone marrow |
Treatment: cell suspension were incubated with CD3e, B220, CD11b, GR1, TER119, CD117 and Flt3 Strain: C57BL/6 Genotype: wildtype Source: DN2 cells Age: adult |
Permissive
Robust
|
Mus musculus |
GSE90958
...
|
MA0139.1
|
| CTCF |
bone marrow |
Treatment: cell suspension were incubated with CD3e, B220, CD11b, GR1, TER119, CD117 and Flt3 Strain: C57BL/6 Genotype: ThymoD+/p(A) Source: DN2 cells Age: adult |
Permissive
Robust
|
Mus musculus |
GSE90958
...
|
MA0139.1
|
| CTCF |
bone marrow |
Treatment: cell suspension were incubated with CD3e, B220, CD11b, GR1, TER119, CD117 and Flt3 Strain: C57BL/6 Genotype: ThymoD+/p(A) Source: DN2 cells Age: adult |
Permissive
Robust
|
Mus musculus |
GSE90958
...
|
MA0139.1
|
| CTCF |
bone marrow |
Treatment: cell suspension were incubated with CD3e, B220, CD11b, GR1, TER119, CD117 and Flt3 Strain: C57BL/6 Genotype: ThymoDp(A)/p(A) Source: DN2 cells Age: adult |
Permissive
Robust
|
Mus musculus |
GSE90958
...
|
MA0139.1
|
| CTCF |
AML12 |
Treatment: shRNA infected, shCtrl Genotype: wildtype |
Permissive
Robust
|
Mus musculus |
GSE95113
...
|
MA0139.1
|
| CTCF |
AML12 |
Treatment: shRNA infected, shU Genotype: HNRNPU knockdown |
Permissive
Robust
|
Mus musculus |
GSE95113
...
|
MA0139.1
|
| CTCF |
in-vitro differentiated neural progenitor cells (NPC) |
Genotype: Sox1-GFP Protocol: sorting GFP+ |
Permissive
Robust
|
Mus musculus |
GSE96107
...
|
MA0139.1
|
| CTCF |
in-vitro differentiated neural progenitor cells (NPC) |
Genotype: Sox1-GFP Protocol: sorting GFP+ |
Permissive
Robust
|
Mus musculus |
GSE96107
...
|
MA0139.1
|
| CTCF |
in-vitro differentiated cortical neurons (CN) |
Genotype: Tau-GFP Protocol: sorting GFP+ |
Permissive
Robust
|
Mus musculus |
GSE96107
...
|
MA0139.1
|
| CTCF |
in-vitro differentiated cortical neurons (CN) |
Genotype: Tau-GFP Protocol: sorting GFP+ |
Permissive
Robust
|
Mus musculus |
GSE96107
...
|
MA0139.1
|
| CTCF |
embryonic stem cells |
Genotype: Oct4-GFP Protocol: sorting GFP+ |
Permissive
Robust
|
Mus musculus |
GSE96107
...
|
MA0139.1
|
| CTCF |
primary cells (short term) |
Treatment: C/EBPa was induced with beta-estradiol, day2 |
Permissive
Robust
|
Mus musculus |
GSE96548
...
|
MA0139.1
|
| CTCF |
primary cells (short term) |
Treatment: C/EBPa was induced with beta-estradiol, day4 |
Permissive
Robust
|
Mus musculus |
GSE96548
...
|
MA0139.1
|
| CTCF |
primary cells (short term) |
Treatment: C/EBPa was induced with beta-estradiol, day6 |
Permissive
Robust
|
Mus musculus |
GSE96548
...
|
MA0139.1
|
| CTCF |
primary cells (short term) |
Treatment: C/EBPa was induced with beta-estradiol, day8 |
Permissive
Robust
|
Mus musculus |
GSE96548
...
|
MA0139.1
|
| CTCF |
cardiac myocytes |
Tissue: Left ventricle Strain :C57BL/6 Genotype: wildtype |
Permissive
Robust
|
Mus musculus |
GSE96691
...
|
MA0139.1
|
| CTCF |
cardiac myocytes |
Tissue: Left ventricle Strain :C57BL/6 Genotype: CTCF knockout |
Permissive
Robust
|
Mus musculus |
GSE96691
...
|
MA0139.1
|
| CTCF |
jejunal epithelial cells |
Treatment: sunflower oil (vehicle for tamoxifen) Genotype: wildtype (Cdx2 f/f (cdx2 knockout)) Strain: B6, 129 mixed background Source: Mouse intestinal villus epithelial cells Cell type: Adult differentiated jejunal epithelial cell, middle 1/3 of intestine |
Permissive
Robust
|
Mus musculus |
GSE98724
...
|
MA0139.1
|
| CTCF |
embryonic stem cells |
Genotype: wildtype Strain: C57bl/6 |
Permissive
Robust
|
Mus musculus |
GSE99530
...
|
MA0139.1
|
| CTCF |
embryonic stem cells |
Genotype: mll2 knockout by Cre-recombination Strain: C57bl/6 |
Permissive
Robust
|
Mus musculus |
GSE99530
...
|
MA0139.1
|
| CTCF |
embryonic stem cells-derived clonal neural progenitor cells |
Source: neural progenitor cells Genotype: wildtype |
Permissive
Robust
|
Mus musculus |
GSE99991
...
|
MA0139.1
|
| CTCF |
embryonic stem cells-derived clonal neural progenitor cells |
Source: neural progenitor cells Genotype: Smchd1-/- |
Permissive
Robust
|
Mus musculus |
GSE99991
...
|
MA0139.1
|
| CTCF |
embryonic stem cells-derived clonal neural progenitor cells |
Source: neural progenitor cells Genotype: wildtype |
Permissive
Robust
|
Mus musculus |
GSE99991
...
|
MA0139.1
|
| CTCF |
embryonic stem cells-derived clonal neural progenitor cells |
Source: neural progenitor cells Genotype: Smchd1-/- |
Permissive
Robust
|
Mus musculus |
GSE99991
...
|
MA0139.1
|
| CTCF |
T47D (invasive ductal carcinoma) |
Treatment: no stress Source: T47D whole cell |
Permissive
Robust
|
Homo sapiens |
GSE111923
...
|
MA0139.1
|
| CTCF |
T47D (invasive ductal carcinoma) |
Treatment: 110 mM NaCl for 7.5 min Source: T47D whole cell |
Permissive
Robust
|
Homo sapiens |
GSE111923
...
|
MA0139.1
|
| CTCF |
T47D (invasive ductal carcinoma) |
Treatment: 110 mM NaCl for 60 min Source: T47D whole cell |
Permissive
Robust
|
Homo sapiens |
GSE111923
...
|
MA0139.1
|
| CTCF |
T47D (invasive ductal carcinoma) |
Treatment: no stress Source: T47D whole cell |
Permissive
Robust
|
Homo sapiens |
GSE111923
...
|
MA0139.1
|
| CTCF |
T47D (invasive ductal carcinoma) |
Treatment: 110 mM NaCl for 7.5 min Source: T47D whole cell |
Permissive
Robust
|
Homo sapiens |
GSE111923
...
|
MA0139.1
|
| CTCF |
T47D (invasive ductal carcinoma) |
Treatment: 110 mM NaCl for 30 min Source: T47D whole cell |
Permissive
Robust
|
Homo sapiens |
GSE111923
...
|
MA0139.1
|
| CTCF |
T47D (invasive ductal carcinoma) |
Treatment: 110 mM NaCl for 60 min Source: T47D whole cell |
Permissive
Robust
|
Homo sapiens |
GSE111923
...
|
MA0139.1
|
| CTCF |
T47D (invasive ductal carcinoma) |
Treatment: no stress Source: T47D whole cell |
Permissive
Robust
|
Homo sapiens |
GSE111923
...
|
MA0139.1
|
| CTCF |
T47D (invasive ductal carcinoma) |
Treatment: triploide, no stress Source: T47D whole cell |
Permissive
Robust
|
Homo sapiens |
GSE111923
...
|
MA0139.1
|
| CTCF |
T47D (invasive ductal carcinoma) |
Treatment: 110 mM NaCl for 60 min Source: T47D whole cell |
Permissive
Robust
|
Homo sapiens |
GSE111923
...
|
MA0139.1
|
| CTCF |
T47D (invasive ductal carcinoma) |
Treatment: 110 mM NaCl for 60 min + triptolide Source: T47D whole cell |
Permissive
Robust
|
Homo sapiens |
GSE111923
...
|
MA0139.1
|
| CTCF |
T47D (invasive ductal carcinoma) |
Treatment: pre treatment with 500 nM triptolide for 2 hrs, 110 mM NaCl for 60 min + triptolide Source: T47D whole cell |
Permissive
Robust
|
Homo sapiens |
GSE111923
...
|
MA0139.1
|
| CTCF |
T47D (invasive ductal carcinoma) |
110 mM NaCl |
Permissive
Robust
|
Homo sapiens |
GSE111923
...
|
MA0139.1
|
| CTCF |
EOL-1 (Acute myeloid leukemia) |
Treatment: untreated |
Permissive
Robust
|
Homo sapiens |
GSE113040
...
|
MA0139.1
|
| CTCF |
MOLM-13(acute monocytic leukemia(AML), Homo sapiens) |
Treatment: treated with 1:10.000 DMSO for 48hr |
Permissive
Robust
|
Homo sapiens |
GSE113040
...
|
MA0139.1
|
| CTCF |
SYO-1(Biphasic synovial sarcoma) |
Treatment: lentivirally infected with shControl |
Permissive
Robust
|
Homo sapiens |
GSE113040
...
|
MA0139.1
|
| CTCF |
Jurkat (T-cells) |
Treatment: untreated |
Permissive
Robust
|
Homo sapiens |
GSE113040
...
|
MA0139.1
|
| CTCF |
TTC-1240 (Rhabdoid tumor of the kidney) |
Treatment: lentivirally infected with empty vector control |
Permissive
Robust
|
Homo sapiens |
GSE113040
...
|
MA0139.1
|
| CTCF |
EndoC-BH1 (human pancreatic beta cell line) |
Source: Pancreas |
Permissive
Robust
|
Homo sapiens |
GSE118588
...
|
MA0139.1
|
| CTCF |
clonal MEF |
Clone: Wt2A1 Genotype: wildtype Sex:female Background genotype: Inter-specific: F2, M.m.domesticus FVB x M.m.Castaneus |
Permissive
Robust
|
Mus musculus |
GSE111820
...
|
MA0139.1
|
| CTCF |
clonal MEF |
Clone: Mut5A6 Genotype: SmcHD1 MomeD1 mutant Sex:female Background genotype: Inter-specific: F2, M.m.domesticus FVB x M.m.Castaneus |
Permissive
Robust
|
Mus musculus |
GSE111820
...
|
MA0139.1
|
| CTCF |
clonal MEF |
Clone: Wt2A1 Genotype: wildtype Sex:female Background genotype: Inter-specific: F2, M.m.domesticus FVB x M.m.Castaneus |
Permissive
Robust
|
Mus musculus |
GSE111820
...
|
MA0139.1
|
| CTCF |
clonal MEF |
Clone: Mut5A6 Genotype: SmcHD1 MomeD1 mutant Sex:female Background genotype: Inter-specific: F2, M.m.domesticus FVB x M.m.Castaneus |
Permissive
Robust
|
Mus musculus |
GSE111820
...
|
MA0139.1
|
| CTCF |
clonal MEF |
Clone: A3-3 Genotype: CRISPR knockout of SmcHD1 Sex:female Background genotype: Inter-specific: F2, M.m.domesticus FVB x M.m.Castaneus |
Permissive
Robust
|
Mus musculus |
GSE111820
...
|
MA0139.1
|
| CTCF |
clonal MEF |
Clone: D4 Genotype: CRISPR knockout of SmcHD1 Sex:female Background genotype: Inter-specific: F2, M.m.domesticus FVB x M.m.Castaneus |
Permissive
Robust
|
Mus musculus |
GSE111820
...
|
MA0139.1
|
| CTCF |
clonal MEF |
Clone: Wt2A1 Genotype: wildtype Sex:female Background genotype: Inter-specific: F2, M.m.domesticus FVB x M.m.Castaneus |
Permissive
Robust
|
Mus musculus |
GSE111820
...
|
MA0139.1
|
| CTCF |
clonal MEF |
Clone: Mut5A6 Genotype: SmcHD1 MomeD1 mutant Sex:female Background genotype: Inter-specific: F2, M.m.domesticus FVB x M.m.Castaneus |
Permissive
Robust
|
Mus musculus |
GSE111820
...
|
MA0139.1
|
| CTCF |
clonal MEF |
Clone: A3-3 Genotype: CRISPR knockout of SmcHD1 Sex:female Background genotype: Inter-specific: F2, M.m.domesticus FVB x M.m.Castaneus |
Permissive
Robust
|
Mus musculus |
GSE111820
...
|
MA0139.1
|
| CTCF |
clonal MEF |
Clone: D4 Genotype: CRISPR knockout of SmcHD1 Sex:female Background genotype: Inter-specific: F2, M.m.domesticus FVB x M.m.Castaneus |
Permissive
Robust
|
Mus musculus |
GSE111820
...
|
MA0139.1
|
| CTCF |
G4 (embryonic stem cells) |
Developmental stage: E11.5 Genotype: Inv1 |
Permissive
Robust
|
Mus musculus |
GSE116790
...
|
MA0139.1
|
| CTCF |
G4 (embryonic stem cells) |
Developmental stage: E11.5 Genotype: Inv1DelCTCF |
Permissive
Robust
|
Mus musculus |
GSE116790
...
|
MA0139.1
|
| CTCF |
G4 (embryonic stem cells) |
Genotype: Inv1 |
Permissive
Robust
|
Mus musculus |
GSE116790
...
|
MA0139.1
|
| CTCF |
embryoid body (day 6) |
Strain: Outbred - B6:129Sv Passage: From 8 to 12 Age: day 6 Cell type: Day 6 embryoid bodies from mouse embryonic stem cells |
Permissive
Robust
|
Mus musculus |
GSE119874
...
|
MA0139.1
|
| CTCF |
clonal MEF |
Genotype: wildtype Clone: Wt2A1 Genetic background: Inter-specific: F2, M.m.domesticus FVB x M.m.Castaneus Sex: female |
Permissive
Robust
|
Mus musculus |
GSE122019
...
|
MA0139.1
|
| CTCF |
clonal MEF |
Genotype: wildtype Clone: Wt2A1 Genetic background: Inter-specific: F2, M.m.domesticus FVB x M.m.Castaneus Sex: female |
Permissive
Robust
|
Mus musculus |
GSE122019
...
|
MA0139.1
|
| CTCF |
clonal MEF |
Genotype: wildtype Clone: Wt2A1 Genetic background: Inter-specific: F2, M.m.domesticus FVB x M.m.Castaneus Sex: female |
Permissive
Robust
|
Mus musculus |
GSE122019
...
|
MA0139.1
|
| CTCF |
clonal MEF |
Genotype: SmcHD1 MomeD1 mutant Clone: Mut5A6 Genetic background: Inter-specific: F2, M.m.domesticus FVB x M.m.Castaneus Sex: female |
Permissive
Robust
|
Mus musculus |
GSE122019
...
|
MA0139.1
|
| CTCF |
clonal MEF |
Genotype: SmcHD1 MomeD1 mutant Clone: Mut5A6 Genetic background: Inter-specific: F2, M.m.domesticus FVB x M.m.Castaneus Sex: female |
Permissive
Robust
|
Mus musculus |
GSE122019
...
|
MA0139.1
|
| CTCF |
clonal MEF |
Genotype: SmcHD1 MomeD1 mutant Clone: Mut5A6 Genetic background: Inter-specific: F2, M.m.domesticus FVB x M.m.Castaneus Sex: female |
Permissive
Robust
|
Mus musculus |
GSE122019
...
|
MA0139.1
|
| CTCF |
HNEK (epidermal keratinocytes) |
Treatment: None; |
Permissive
Robust
|
Homo sapiens |
GSE29611
...
|
MA0139.1
|
| CTCF |
HepG2 (hepatoblastoma) |
Treatment: None; |
Permissive
Robust
|
Homo sapiens |
GSE29611
...
|
MA0139.1
|
| CTCF |
WA01 (H1, human embryonic stem cells) |
Treatment: None; |
Permissive
Robust
|
Homo sapiens |
GSE29611
...
|
MA0139.1
|
| CTCF |
NHLF (lung fibroblasts) |
Treatment: None; |
Permissive
Robust
|
Homo sapiens |
GSE29611
...
|
MA0139.1
|
| CTCF |
HUVEC-C (HUVEC, umbilical vein endothelial cells) |
Treatment: None; |
Permissive
Robust
|
Homo sapiens |
GSE29611
...
|
MA0139.1
|
| CTCF |
K562 (myelogenous leukemia) |
Treatment: None; |
Permissive
Robust
|
Homo sapiens |
GSE29611
...
|
MA0139.1
|
| CTCF |
HMEC (human mammary epithelial cells) |
Treatment: None; |
Permissive
Robust
|
Homo sapiens |
GSE29611
...
|
MA0139.1
|
| CTCF |
NHDF-Ad (adult dermal fibroblasts) |
Treatment: None; |
Permissive
Robust
|
Homo sapiens |
GSE29611
...
|
MA0139.1
|
| CTCF |
GM12878 (female B-cells lymphoblastoid cell line) |
Treatment: None; |
Permissive
Robust
|
Homo sapiens |
GSE29611
...
|
MA0139.1
|
| CTCF |
HSMM (skeletal muscle myoblasts) |
Treatment: None; |
Permissive
Robust
|
Homo sapiens |
GSE29611
...
|
MA0139.1
|
| CTCF |
NA-A (astrocytes) |
Treatment: None; |
Permissive
Robust
|
Homo sapiens |
GSE29611
...
|
MA0139.1
|
| CTCF |
HSMM dirived skeletal muscle myotubes |
Treatment: None; |
Permissive
Robust
|
Homo sapiens |
GSE29611
...
|
MA0139.1
|
| CTCF |
osteoblasts |
Treatment: None; |
Permissive
Robust
|
Homo sapiens |
GSE29611
...
|
MA0139.1
|
| CTCF |
HeLa S3 (cervical adenocarcinoma) |
Treatment: None; |
Permissive
Robust
|
Homo sapiens |
GSE29611
...
|
MA0139.1
|
| CTCF |
DND41 (acute lymphoblastic leukemia) |
Treatment: None; |
Permissive
Robust
|
Homo sapiens |
GSE29611
...
|
MA0139.1
|
| CTCF |
CD20+ |
Treatment: None; |
Permissive
Robust
|
Homo sapiens |
GSE29611
...
|
MA0139.1
|
| CTCF |
RO01746 (CD14+ monocytes) |
Treatment: None; |
Permissive
Robust
|
Homo sapiens |
GSE29611
...
|
MA0139.1
|
| CTCF |
A549 (lung carcinoma) |
Treatment: 1 h with 0.02% Ethanol; |
Permissive
Robust
|
Homo sapiens |
GSE29611
...
|
MA0139.1
|
| CTCF |
A549 (lung carcinoma) |
Treatment: 1 h with 100 nM Dexamethasone; |
Permissive
Robust
|
Homo sapiens |
GSE29611
...
|
MA0139.1
|
| CTCF |
HAP1 (chronic myelogenous leukemia) |
Genotype: wildtype; |
Permissive
Robust
|
Homo sapiens |
GSE94992
...
|
MA0139.1
|
| CTCF |
HAP1 (chronic myelogenous leukemia) |
Genotype: Wapl and SCC4 knockout; |
Permissive
Robust
|
Homo sapiens |
GSE94992
...
|
MA0139.1
|
| CTCF |
whole brain |
Developmental stage: Embryonic day 14.5; |
Permissive
Robust
|
Mus musculus |
GSE36027
...
|
MA0139.1
|
| CTCF |
trophoblast stem cells |
Strain: CD1(ICR); Developmental stage: blastocysts, cecle stage G1; |
Permissive
|
Mus musculus |
GSE41371
...
|
MA0139.1
|
| CTCF |
trophoblast stem cells |
Strain: CD1(ICR); Developmental stage: blastocysts, S cycle stage; |
Permissive
|
Mus musculus |
GSE41371
...
|
MA0139.1
|
| CTCF |
trophoblast stem cells |
Strain: CD1(ICR); Developmental stage: blastocysts, cycle stage M; |
Permissive
Robust
|
Mus musculus |
GSE41371
...
|
MA0139.1
|
| CTCF |
embryonic fibroblasts |
Strain: mixed C57BL/6 and 129 background; Genotype: Wapl +/delta; Treatment: 4-OHT was added to the starvation medium to a final concentration of 500 nM; |
Permissive
Robust
|
Mus musculus |
GSE41602
...
|
MA0139.1
|
| CTCF |
embryonic fibroblasts |
Strain: mixed C57BL/6 and 129 background; Genotype: Wapl -/delta; Treatment: 4-OHT was added to the starvation medium to a final concentration of 500 nM; |
Permissive
Robust
|
Mus musculus |
GSE41602
...
|
MA0139.1
|
| CTCF |
pancreas |
Strain: C57BL/6; Age: 8-10 week old; |
Permissive
Robust
|
Mus musculus |
GSE59119
...
|
MA0139.1
|
| CTCF |
MCF7L-P(immortalized breast epithelial cell line) |
Treatment: untreated; |
Permissive
Robust
|
Homo sapiens |
GSE108787
...
|
MA0139.1
|
| CTCF |
MCF7L-P(immortalized breast epithelial cell line) |
Treatment: treated with E2 for 1 hr; |
Permissive
Robust
|
Homo sapiens |
GSE108787
...
|
MA0139.1
|
| CTCF |
MCF7L-P(immortalized breast epithelial cell line) |
Treatment: treated with E2 for 4 hrs; |
Permissive
Robust
|
Homo sapiens |
GSE108787
...
|
MA0139.1
|
| CTCF |
MCF7L-P(immortalized breast epithelial cell line) |
Treatment: treated with E2 for 16 hrs; |
Permissive
Robust
|
Homo sapiens |
GSE108787
...
|
MA0139.1
|
| CTCF |
MCF7L-P(immortalized breast epithelial cell line) |
Treatment: treated with E2 for 24 hrs; |
Permissive
Robust
|
Homo sapiens |
GSE108787
...
|
MA0139.1
|
| CTCF |
olfactory neurons |
Genotype: tetotet3iresgfp, omptta (overexpressing Tet3); |
Permissive
Robust
|
Mus musculus |
GSE115862
...
|
MA0139.1
|
| CTCF |
olfactory neurons |
Genotype: tetogfp, omptta; |
Permissive
Robust
|
Mus musculus |
GSE115862
...
|
MA0139.1
|
| CTCF |
MDA-MB-157 (triple negative breast carcinoma) |
Treatment: untreated; |
Permissive
Robust
|
Homo sapiens |
GSE116868
...
|
MA0139.1
|
| CTCF |
HT1080 (fibrosarcoma) |
Treatment: none; |
Permissive
Robust
|
Homo sapiens |
GSE122462
...
|
MA0139.1
|
| CTCF |
HT1080 (fibrosarcoma) |
Treatment: 3 uM final concentration of CBL0137 for 6hrs; |
Permissive
Robust
|
Homo sapiens |
GSE122462
...
|
MA0139.1
|
| CTCF |
HT1080 (fibrosarcoma) |
Treatment: none; |
Permissive
Robust
|
Homo sapiens |
GSE122462
...
|
MA0139.1
|
| CTCF |
HT1080 (fibrosarcoma) |
Treatment: 3 uM final concentration of CBL0137 for 6hrs; |
Permissive
Robust
|
Homo sapiens |
GSE122462
...
|
MA0139.1
|
| CTCF |
telencephalon |
Developmental stage: E13.5; |
Permissive
Robust
|
Mus musculus |
GSE105071
...
|
MA0139.1
|
| CTCF |
medial ganglionic eminence |
Developmental stage: E13.5; |
Permissive
Robust
|
Mus musculus |
GSE105071
...
|
MA0139.1
|
| CTCF |
embryonic stem cells |
Strain: 129S6/SvEvTac; Genotype: wildtype; |
Permissive
Robust
|
Mus musculus |
GSE112132
...
|
MA0139.1
|
| CTCF |
embryonic stem cells |
Strain: 129S6/SvEvTac; Genotype: Snf2h knockout; |
Permissive
Robust
|
Mus musculus |
GSE112132
...
|
MA0139.1
|
| CTCF |
embryonic stem cells |
Strain: 129S6/SvEvTac; Genotype: wildtype; |
Permissive
Robust
|
Mus musculus |
GSE112132
...
|
MA0139.1
|
| CTCF |
embryonic stem cells |
Strain: 129S6/SvEvTac; Genotype: wildtype; |
Permissive
Robust
|
Mus musculus |
GSE112132
...
|
MA0139.1
|
| CTCF |
embryonic stem cells |
Strain: 129S6/SvEvTac; Genotype: Brg1 knockout; |
Permissive
Robust
|
Mus musculus |
GSE112132
...
|
MA0139.1
|
| CTCF |
embryonic stem cells |
Strain: 129S6/SvEvTac; Genotype: Brg1 knockout; |
Permissive
Robust
|
Mus musculus |
GSE112132
...
|
MA0139.1
|
| CTCF |
embryonic stem cells |
Strain: 129S6/SvEvTac; Genotype: Snf2h knockout, Snf2h wiltype add-back; |
Permissive
Robust
|
Mus musculus |
GSE112132
...
|
MA0139.1
|
| CTCF |
embryonic stem cells |
Strain: 129S6/SvEvTac; Genotype: Snf2h ko, Snf2h mutant add-back; |
Permissive
Robust
|
Mus musculus |
GSE112132
...
|
MA0139.1
|
| CTCF |
mESCs (mouse embryonic stem cells) |
Genotype: TET1/2 double knockout; |
Permissive
Robust
|
Mus musculus |
GSE114599
...
|
MA0139.1
|
| CTCF |
mESCs (mouse embryonic stem cells) |
Genotype: TET1/2 double knockout; |
Permissive
Robust
|
Mus musculus |
GSE114599
...
|
MA0139.1
|
| CTCF |
mESCs (mouse embryonic stem cells) |
Genotype: wildtype; |
Permissive
Robust
|
Mus musculus |
GSE114599
...
|
MA0139.1
|
| CTCF |
mESCs (mouse embryonic stem cells) |
Genotype: wildtype; |
Permissive
Robust
|
Mus musculus |
GSE114599
...
|
MA0139.1
|
| CTCF |
embryonic stem cells |
Treatment: none; Strain: CAST/Ei x 129/Sv/Jae; Genotype: CTCF Ser224-P phospho-mimic mutant; |
Permissive
Robust
|
Mus musculus |
GSE119697
...
|
MA0139.1
|
| CTCF |
embryonic stem cells |
Treatment: none; Strain: CAST/Ei x 129/Sv/Jae; Genotype: CTCF Ser224-P phospho-mimic mutant; |
Permissive
Robust
|
Mus musculus |
GSE119697
...
|
MA0139.1
|
| CTCF |
embryonic stem cells |
Treatment: no doxycycline; Developmental stage: day4 of differentiation; |
Permissive
Robust
|
Mus musculus |
GSE126362
...
|
MA0139.1
|
| CTCF |
embryonic stem cells |
Treatment: doxycycline for 1 day; Developmental stage: day4 of differentiation; |
Permissive
Robust
|
Mus musculus |
GSE126362
...
|
MA0139.1
|
| CTCF |
embryonic stem cells |
Treatment: no doxycycline; Developmental stage: day4 of differentiation; |
Permissive
Robust
|
Mus musculus |
GSE126362
...
|
MA0139.1
|
| CTCF |
embryonic stem cells |
Treatment: doxycycline for 1 day; Developmental stage: day4 of differentiation; |
Permissive
Robust
|
Mus musculus |
GSE126362
...
|
MA0139.1
|
| CTCF |
HPC7 (haematopoietic multipotent progenitors) |
Genotype: Luc knockdown; Treatment: 94 hours knockdown induction with Doxycycline; |
Permissive
Robust
|
Mus musculus |
GSE129478
...
|
MA0139.1
|
| CTCF |
HPC7 (haematopoietic multipotent progenitors) |
Genotype: Luc knockdown; Treatment: 95 hours knockdown induction with Doxycycline; |
Permissive
Robust
|
Mus musculus |
GSE129478
...
|
MA0139.1
|
| CTCF |
HPC7 (haematopoietic multipotent progenitors) |
Genotype: Stag2 knockdown; Treatment: 96 hours knock-down induction with Doxycycline with shStag2; |
Permissive
Robust
|
Mus musculus |
GSE129478
...
|
MA0139.1
|
| CTCF |
HPC7 (haematopoietic multipotent progenitors) |
Genotype: Stag2 knockdown; Treatment: 97 hours knock-down induction with Doxycycline with shStag2; |
Permissive
Robust
|
Mus musculus |
GSE129478
...
|
MA0139.1
|
| CTCF |
HPC7 (haematopoietic multipotent progenitors) |
Genotype: Rad21 knockdown; Treatment: 98 hours knock-down induction with Doxycycline with shRad21; |
Permissive
Robust
|
Mus musculus |
GSE129478
...
|
MA0139.1
|
| CTCF |
HPC7 (haematopoietic multipotent progenitors) |
Genotype: Rad21 knockdown; Treatment: 99 hours knock-down induction with Doxycycline with shRad21; |
Permissive
Robust
|
Mus musculus |
GSE129478
...
|
MA0139.1
|
| CTCF |
HPC7 derived erythroid cells |
Conditions: 4 U/l EPO; Genotype: Luc knockdown; Treatment: 80 hours knockdown induction with Doxycycline; |
Permissive
Robust
|
Mus musculus |
GSE129478
...
|
MA0139.1
|
| CTCF |
HPC7 derived erythroid cells |
Conditions: 4 U/l EPO; Genotype: Luc knockdown; Treatment: 81 hours knockdown induction with Doxycycline; |
Permissive
Robust
|
Mus musculus |
GSE129478
...
|
MA0139.1
|
| CTCF |
HPC7 derived erythroid cells |
Conditions: 4 U/l EPO; Genotype: Stag2 knockdown; Treatment: 82 hours knock-down induction with Doxycycline; |
Permissive
Robust
|
Mus musculus |
GSE129478
...
|
MA0139.1
|
| CTCF |
myeloid malignancies |
Conditions: 50 ng/ul IL-3; Genotype: Luc knockdown; Treatment: 76 hours knockdown induction with Doxycycline; |
Permissive
Robust
|
Mus musculus |
GSE129478
...
|
MA0139.1
|
| CTCF |
myeloid malignancies |
Conditions: 50 ng/ul IL-3; Genotype: Luc knockdown; Treatment: 77 hours knockdown induction with Doxycycline; |
Permissive
Robust
|
Mus musculus |
GSE129478
...
|
MA0139.1
|
| CTCF |
fetal limb bud and midbrain |
Genotype: deltaCTCF i4; Developmental stage: E10.5; Strain: G4; |
Permissive
Robust
|
Mus musculus |
GSE123386
...
|
MA0139.1
|
| CTCF |
fetal limb bud and midbrain |
Genotype: deltaCTCF i5; Developmental stage: E10.5; Strain: G4; |
Permissive
Robust
|
Mus musculus |
GSE123386
...
|
MA0139.1
|
| CTCF |
fetal limb bud and midbrain |
Genotype: wildtype CTCF; Developmental stage: E10.5; Strain: G4; |
Permissive
Robust
|
Mus musculus |
GSE123386
...
|
MA0139.1
|
| CTCF |
fetal limb bud and midbrain |
Genotype: delta-CTCF i4i5ZRSreg; Developmental stage: E10.5; Strain: G4; |
Permissive
Robust
|
Mus musculus |
GSE123386
...
|
MA0139.1
|
| CTCF |
fetal limb bud and midbrain |
Genotype: deltaCTCF i4i5; Developmental stage: E10.5; Strain: G4; |
Permissive
Robust
|
Mus musculus |
GSE123386
...
|
MA0139.1
|
| CTCF |
fetal limb bud and midbrain |
Genotype: deltaCTCF i4i5ZRS; Developmental stage: E10.5; Strain: G4; |
Permissive
Robust
|
Mus musculus |
GSE123386
...
|
MA0139.1
|
| CTCF |
fetal limb bud and midbrain |
Genotype: wildtype; Developmental stage: E10.5; Strain: Bl.6; |
Permissive
Robust
|
Mus musculus |
GSE123386
...
|
MA0139.1
|
| CTCF |
cerebellum |
Genotype: Ai32 fl/fl; Age: 6-8weeks; |
Permissive
Robust
|
Mus musculus |
GSE127995
...
|
MA0139.1
|
| CTCF |
cerebellum |
Genotype: Atoh1-CRE, Ai32 fl/fl; Age: 6-8weeks; |
Permissive
Robust
|
Mus musculus |
GSE127995
...
|
MA0139.1
|
| CTCF |
Abelson-transformed pre-B cell |
Genotype: Lig4-/-(knockout); Strain: C57BL/6; |
Permissive
Robust
|
Mus musculus |
GSE129526
...
|
MA0139.1
|
| CTCF |
bone-marrow derived primary pre B cells |
Age: adult; Strain: C57BL/6 x 129/Sv; Source: large pre-B; Genotype: wildtype; |
Permissive
Robust
|
Mus musculus |
GSE130315
...
|
MA0139.1
|
| CTCF |
E14TG2A (embryonic stem cells) |
Conditions: cultured in 2i medium for 3 days; |
Permissive
Robust
|
Mus musculus |
GSE92407
...
|
MA0139.1
|
| CTCF |
E14TG2A (embryonic stem cells) |
Conditions: cultured in EpiLSCs medium; |
Permissive
Robust
|
Mus musculus |
GSE92407
...
|
MA0139.1
|
| CTCF |
E14TG2A (embryonic stem cells) |
Conditions: cultured in serum medium; |
Permissive
Robust
|
Mus musculus |
GSE92407
...
|
MA0139.1
|
| CTCF |
MCF7 (Invasive ductal breast carcinoma) |
TAM |
Permissive
Robust
|
Homo sapiens |
ERP000783
|
MA0139.1
|
| CTCF |
|
BLOOD |
Permissive
Robust
|
Homo sapiens |
GSE43098
|
MA0139.1
|
| CTCF |
|
blood |
Permissive
Robust
|
Homo sapiens |
GSE46832
|
MA0139.1
|
| CTCF |
|
naive |
Permissive
|
Homo sapiens |
GSE74850
|
MA0139.1
|
| CTCF |
RCC 7860 (Renal cell carcinoma) |
NORMOXIA |
Permissive
Robust
|
Homo sapiens |
GSE78113
|
MA0139.1
|
| CTCF |
MCF7 (Invasive ductal breast carcinoma) |
|
Permissive
Robust
|
Homo sapiens |
ENCSR000AHD
|
MA0139.1
|
| CTCF |
GM12878 (female B-cells lymphoblastoid cell line) |
|
Permissive
Robust
|
Homo sapiens |
ENCSR000AKB
|
MA0139.1
|
| CTCF |
K562 (myelogenous leukemia) |
|
Permissive
Robust
|
Homo sapiens |
ENCSR000AKO
|
MA0139.1
|
| CTCF |
HUVEC-C (HUVEC, umbilical vein endothelial cells) |
|
Permissive
Robust
|
Homo sapiens |
ENCSR000ALA
|
MA0139.1
|
| CTCF |
keratinocytes |
|
Permissive
Robust
|
Homo sapiens |
ENCSR000ALJ
|
MA0139.1
|
| CTCF |
mammary epithelial cells |
|
Permissive
Robust
|
Homo sapiens |
ENCSR000ALV
|
MA0139.1
|
| CTCF |
HepG2 (hepatoblastoma) |
|
Permissive
Robust
|
Homo sapiens |
ENCSR000AMA
|
MA0139.1
|
| CTCF |
WA01 (H1, human embryonic stem cells) |
|
Permissive
Robust
|
Homo sapiens |
ENCSR000AMF
|
MA0139.1
|
| CTCF |
skeletal muscles and myoblasts |
|
Permissive
Robust
|
Homo sapiens |
ENCSR000ANE
|
MA0139.1
|
| CTCF |
normal lung fibroblasts |
|
Permissive
Robust
|
Homo sapiens |
ENCSR000ANO
|
MA0139.1
|
| CTCF |
myotube |
|
Permissive
Robust
|
Homo sapiens |
ENCSR000ANS
|
MA0139.1
|
| CTCF |
HeLa S3 (cervical adenocarcinoma) |
|
Permissive
Robust
|
Homo sapiens |
ENCSR000AOA
|
MA0139.1
|
| CTCF |
astrocytes |
|
Permissive
Robust
|
Homo sapiens |
ENCSR000AOO
|
MA0139.1
|
| CTCF |
osteoblasts |
|
Permissive
Robust
|
Homo sapiens |
ENCSR000APF
|
MA0139.1
|
| CTCF |
fibroblast of dermis |
|
Permissive
Robust
|
Homo sapiens |
ENCSR000APM
|
MA0139.1
|
| CTCF |
DND41 (acute lymphoblastic leukemia) |
|
Permissive
Robust
|
Homo sapiens |
ENCSR000AQU
|
MA0139.1
|
| CTCF |
CD14+ monocytes |
|
Permissive
Robust
|
Homo sapiens |
ENCSR000ATN
|
MA0139.1
|
| CTCF |
B-cells |
|
Permissive
Robust
|
Homo sapiens |
ENCSR000AUV
|
MA0139.1
|
| CTCF |
HepG2 (hepatoblastoma) |
|
Permissive
Robust
|
Homo sapiens |
ENCSR000BIE
|
MA0139.1
|
| CTCF |
WA01 (H1, human embryonic stem cells) |
|
Permissive
Robust
|
Homo sapiens |
ENCSR000BNH
|
MA0139.1
|
| CTCF |
K562 (myelogenous leukemia) |
|
Permissive
Robust
|
Homo sapiens |
ENCSR000BPJ
|
MA0139.1
|
| CTCF |
HCT-116 (colon carcinoma) |
|
Permissive
Robust
|
Homo sapiens |
ENCSR000BSE
|
MA0139.1
|
| CTCF |
D54 (H54, Human glioblastoma) |
|
Permissive
Robust
|
Homo sapiens |
ENCSR000DKN
|
MA0139.1
|
| CTCF |
GM10248 (male B-cells) |
|
Permissive
Robust
|
Homo sapiens |
ENCSR000DKP
|
MA0139.1
|
| CTCF |
GM10266 (male B-cells) |
|
Permissive
Robust
|
Homo sapiens |
ENCSR000DKR
|
MA0139.1
|
|
